Japan Approves Stem-Cell Therapies for Parkinson’s, Heart Failure

TOKYO (Web Desk): Japan has approved pioneering stem-cell treatments for Parkinson’s disease and severe heart failure, with the therapies expected to reach patients within months.

Pharmaceutical firm Sumitomo Pharma announced it had received approval to manufacture and sell Amchepry, a treatment that transplants stem cells into a patient’s brain to help restore dopamine-producing cells.

At the same time, Japan’s health ministry approved ReHeart, a therapy developed by startup Cuorips that uses heart muscle cell sheets to stimulate the formation of new blood vessels and improve heart function.

According to media reports, the treatments could be available to patients as early as this summer, making them the world’s first commercially available medical products using induced pluripotent stem (iPS) cells.

The technology is based on groundbreaking research by Shinya Yamanaka, who won the Nobel Prize in Physiology or Medicine for discovering iPS cells capable of developing into almost any type of cell in the human body.

Health Minister Kenichiro Ueno said the approval could bring relief to patients in Japan and around the world. Authorities plan to complete all necessary procedures to make the therapies widely available.

The approval granted to Amchepry is conditional and time-limited, allowing the treatment to reach patients more quickly while additional data is collected.

Clinical trials led by Kyoto University researchers showed promising results. Seven Parkinson’s patients aged between 50 and 69 received stem-cell implants in the brain, and after two years of monitoring, no major side effects were reported. Four participants showed improvements in their symptoms.

Parkinson’s disease is a progressive neurological condition affecting about 10 million people worldwide, according to the Parkinson’s Foundation.